At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 172 enrolled
Drug / intervention
GB0139 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, 52 Week, Double-blind, Multicentre, Parallel, Placebo-controlled Phase 2b Study in Subjects With Idiopathic Pulmonary Fibrosis (IPF) Investigating the Efficacy and Safety of GB0139, an Inhaled Galectin-3 Inhibitor.
In Brief
A Phase 2 clinical trial evaluating GB0139 and Placebo for Idiopathic Pulmonary Fibrosis (IPF). Completed, enrolled 172 participants across 128 sites in 15 countries.
Detailed Summary
This is a randomized, double-blind, placebo-controlled phase 2b trial in subjects with IPF (idiopathic pulmonary fibrosis) investigating the efficacy and safety of GB0139.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsIdiopathic Pulmonary Fibrosis (IPF)
CountriesAustralia, Belgium, Canada, France, Georgia, Germany, Ireland, Israel, Italy, Poland, Russia, Spain, Ukraine, United Kingdom, United States
CollaboratorsSyneos Health, bioRASI, LLC
Timeline
Phase 2CompletedFinished
20192020202120222023202420252026
First PostedFeb 2019
Enrollment StartFeb 2019
Primary CompletionMay 2023
TodayJul 2026
First PostedFeb 6, 2019
Enrollment StartFeb 19, 2019
Primary CompletionMay 17, 2023
TodayJul 2, 2026
Enrollment to primary: 4.2 yearsPosted 7.4 years ago
Interventions
GB0139drug
GB0139 is a galectin-3 inhibitor designed to modulate the fibrogenic response to tissue injury. It is administered as inhalation once a day.
Placebodrug
Placebo is administered as inhalation once a day